Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion.
Raymundo A QuintanaJose BanchsRidhi GuptaHeather Y LinSean D RajAnthony ConleyVinod RaviDejka M AraujoRobert S BenjaminShreyaskumar R PatelSaroj Vadhan-RajNeeta SomaiahPublished in: Sarcoma (2017)
Doxorubicin cardiotoxicity can be limited by administering doxorubicin as a continuous infusion, allowing higher cumulative dosing to maximize efficacy.
Keyphrases